Sugi Predict

Sugi Predict / Compounds / SCHEMBL5937366

SCHEMBL5937366

SCHEMBL5937366

O=C1Nc2ccccc2Nc2ncccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 1.00
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ ALDH1A1 P00352 3/20 0.69
▸ RAB9A P51151 2/20 0.69
▸ NPC1 O15118 1/20 0.69
▸ GAA P10253 1/20 0.69
▸ MAPT P10636 1/20 0.69
▸ CYP2C9 P11712 1/20 0.69
▸ CYP2C19 P33261 1/20 0.69
▸ MCL1 Q07820 1/20 0.69
▸ GSK3B P49841 8/20 0.62
▸ GSK3A P49840 4/20 0.62
▸ CDK5 Q00535 4/20 0.62
▸ CDK2 P24941 4/20 0.62
▸ PLK4 O00444 3/20 0.62
▸ AURKA O14965 3/20 0.62
▸ CHEK2 O96017 3/20 0.62
▸ CSNK1D P48730 3/20 0.62
▸ AURKB Q96GD4 3/20 0.62
▸ STK3 Q13188 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5178865 0.89 CYP1A2 (0.80) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL2420515 0.87 CYP1A2 (0.77) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL11807411 0.83 CYP1A2 (0.71) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL8791690 0.83 ALDH1A1 (0.76) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL8791662 0.82 CYP1A2 (0.70) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL30258763 0.82 CYP1A2 (0.70) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL30259055 0.82 ALDH1A1 (0.70) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL30259191 0.82 ALDH1A1 (0.70) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL9793307 0.80 CYP1A2 (0.67) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL8790953 0.79 CYP1A2 (0.65) CYP1A2SMN1; SMN2ALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1000059-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 — — EP claimed
WO-1999006403-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 — — WO claimed
EP-0393604-B1 6,11-Dihydro-5H-pyrido(2,3-b)(1,5,)benzodiazepin-5-ones and thiones and their use in the prevention or treatment of AIDS BOEHRINGER INGELHEIM PHARMA (US) 1997-12-29 — — EP claimed
US-5571809-A The treatment of HIV-1 infection using certain pyridodiazepines BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1996-11-05 — — US claimed
US-5001122-A Use of diazepinones for treating disorders of the microcirculation DR. KARL THOMAE GMBH (DE) 1991-03-19 — — US claimed
EP-0342474-A2 Use of diazepinones for the preparation of a medicament for therapy of microcirculatory disorders Dr. Karl Thomae GmbH (DE) 1989-11-23 — — EP claimed
US-4841046-A Process for the preparation of pyridobenzodiazepinone DOMPE' FARMACEUTICI S.P.A. (IT) 1989-06-20 — — US claimed
EP-0314163-A2 Process for the preparation of 6,11-dihydro-5H-pyrido(2,3-b)(1,5)benzodiazepin-5-one DOMPE' FARMACEUTICI S.p.A. (IT) 1989-05-03 — — EP claimed
JP-3063274-A — — None — — JP disclosed
WO-2023020416-A1 TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF 勤浩医药（苏州）有限公司 2023-02-23 — — WO disclosed
EP-3226688-B1 TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES MERCK SHARP & DOHME (US) 2020-07-01 — — EP disclosed
EP-3226690-B1 NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES MERCK SHARP & DOHME (US) 2020-05-20 — — EP disclosed
US-10442819-B2 Tricyclic compounds as inhibitors of mutant IDH enzymes MERCK SHARP & DOHME CORP. (US) 2019-10-15 — — US disclosed
US-10086000-B2 Tricyclic compounds as inhibitors of mutant IDH enzymes MERCK SHARP & DOHME CORP. (US) 2018-10-02 — — US disclosed
EP-0314163-A2 Process for the preparation of 6,11-dihydro-5H-pyrido(2,3-b)(1,5)benzodiazepin-5-one DOMPE' FARMACEUTICI S.p.A. (IT) 1989-05-03 — — EP disclosed
US-4594190-A Quaternary salts of dibenzo[1,4]diazepinones, pyrido-[1,4]benzodiazepinones, pyrido[1,5]benzodiazepinones with antiulcer, antisecretory, spasmolytic and antimusarinic activities DOMPE' FARMACEUTICI S.P.A. (IT) 1986-06-10 — — US disclosed
US-4556653-A ANTISECRETORY, ANTIULCER AND ANTISPASMODIC AGENTS DOMPE' FARMACEUTICA S.P.A. (IT) 1985-12-03 — — US disclosed
EP-0126366-A2 Quaternary salts of dibenzo(1,4)diazepinone, pyrido-(1,4)benzodiazepinone, pyrido(1,5)benzodiazepinone derivatives and pharmacological activity thereof DOMPE' FARMACEUTICI S.p.A. (IT) 1984-11-28 — — EP disclosed
US-4167570-A BRONCHOSPASMOLYTICS, BRONCHOSECRETOLYTICS BOEHRINGER INGELHEIM GMBH (DE) 1979-09-11 — — US disclosed
US-4021557-A BRONCHOSPASMOLYTICS BOEHRINGER INGELHEIM GMBH (DT) 1977-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442819-B2 Tricyclic compounds as inhibitors of mutant IDH enzymes IDH3A, IDH2, IDH3B CYP1A2 146/4885SMN1; SMN2 3984/4885ALDH1A1 92/4885
US-10086000-B2 Tricyclic compounds as inhibitors of mutant IDH enzymes IDH3A, IDH3B, IDH2 CYP1A2 157/4885SMN1; SMN2 3733/4885ALDH1A1 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.